Pharmacokinetic Study of Nicotinamide Riboside

Sponsor: University of Washington
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Purpose

Utilize whole blood assay for NR to assess the pharmacokinetics of NR at a maximum dose of 1000mg twice daily, and will collect history, physical examination and laboratory data to determine the safety and tolerability of NR in eight, healthy volunteers. In addition, whole blood NAD+ levels will be measured at each time point, to determine whether this NR dose significantly raises whole blood NAD+ levels

Study Design

Open label, no control

Dose

Dose up-titration: from 250mg/day orally up to 2000mg/day

Length of Intervention

9 days

Status

Completed

Condition or Disease 

Metabolic Disturbance

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Pharmacokinetic/Safety, CompletedANAD Staff